The influence of age on clinical outcomes in patients treated with the resolute zotarolimus-eluting stent

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F16%3AN0000001" target="_blank" >RIV/00064173:_____/16:N0000001 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/16:43908129

Výsledek na webu

<a href="http://dx.doi.org/10.1002/ccd.25334" target="_blank" >http://dx.doi.org/10.1002/ccd.25334</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ccd.25334" target="_blank" >10.1002/ccd.25334</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The influence of age on clinical outcomes in patients treated with the resolute zotarolimus-eluting stent

Popis výsledku v původním jazyce

Aims: To evaluate the rate of clinical events and bleeding risk according to age in patients undergoing percutaneous coronary intervention (PCI) with new-generation drug-eluting stent enrolled in the RESOLUTE Global Clinical Program. Methods: This study represents a pooled analysis of 5 trials included in the RESOLUTE program including 5,130 patients, of whom 1675 (32.6%) were GREATER-THAN OR EQUAL TO70 years old (elderly patients). Results: After adjusting for confounders, age GREATER-THAN OR EQUAL TO70 years was a significant predictor of high mortality at 30 days (0.6% vs. 0.1%, P = 0.017) and two years (7.2% vs. 2%, P < 0.001). No differences were seen with respect to acute myocardial infarction (MI) or target lesion and vessel revascularization rates between young and elderly patients. Bleeding rates were higher in the elderly throughout follow-up. In the elderly, 7 out of 27 (26%) patients with bleeding episodes died, with a median time between bleeding episode to death of 21 days. In the younger population, 1 patient out of 17 with bleeding episode died (400 days later). Conclusion: Elderly patients undergoing PCI with a new-generation drug-eluting stent have an increased mortality and bleeding risk, with similar rates of acute MI and repeat revascularization. Bleeding risk was higher in the elderly and strongly related to death. TLF rates were not significantly different between the 2 age groups suggesting that the R-ZES is effective for patients younger and older than 70 years of age. R-ZES may be recommended for elderly patients when PCI with a DES is identified as a suitable option.

Název v anglickém jazyce

The influence of age on clinical outcomes in patients treated with the resolute zotarolimus-eluting stent

Popis výsledku anglicky

Aims: To evaluate the rate of clinical events and bleeding risk according to age in patients undergoing percutaneous coronary intervention (PCI) with new-generation drug-eluting stent enrolled in the RESOLUTE Global Clinical Program. Methods: This study represents a pooled analysis of 5 trials included in the RESOLUTE program including 5,130 patients, of whom 1675 (32.6%) were GREATER-THAN OR EQUAL TO70 years old (elderly patients). Results: After adjusting for confounders, age GREATER-THAN OR EQUAL TO70 years was a significant predictor of high mortality at 30 days (0.6% vs. 0.1%, P = 0.017) and two years (7.2% vs. 2%, P < 0.001). No differences were seen with respect to acute myocardial infarction (MI) or target lesion and vessel revascularization rates between young and elderly patients. Bleeding rates were higher in the elderly throughout follow-up. In the elderly, 7 out of 27 (26%) patients with bleeding episodes died, with a median time between bleeding episode to death of 21 days. In the younger population, 1 patient out of 17 with bleeding episode died (400 days later). Conclusion: Elderly patients undergoing PCI with a new-generation drug-eluting stent have an increased mortality and bleeding risk, with similar rates of acute MI and repeat revascularization. Bleeding risk was higher in the elderly and strongly related to death. TLF rates were not significantly different between the 2 age groups suggesting that the R-ZES is effective for patients younger and older than 70 years of age. R-ZES may be recommended for elderly patients when PCI with a DES is identified as a suitable option.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Catheterization & Cardiovascular Interventions

ISSN

1522-1946

e-ISSN

—

Svazek periodika

87

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

253-261

Kód UT WoS článku

000370451700018

EID výsledku v databázi Scopus

2-s2.0-84959482474